Treace Medical Concepts, Inc.(TMCI)Earnings, Financials & Key Ratios

TMCI•NASDAQ

$4.56

Price updated Jul 6, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryOrthopedics, spine, and sports medicine

AboutTreace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.Show more

Revenue$213M+1.6%
EBITDA-$44M+7.6%
Net Income-$59M-5.8%
EPS (Diluted)-0.93-3.3%
Gross Margin79.81%-0.7%
EBITDA Margin-20.52%+9.1%
Operating Margin-25.46%+4.3%
Net Margin-27.74%-4.2%
ROE-58.94%-32.6%

TMCI Price & Volume

Treace Medical Concepts, Inc. (TMCI) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operating Losses Threaten Liquidity Runway Stability

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Decelerating

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Liquidity and capital exhaustion

Key Thesis Takeaways

Treace Medical Concepts faces a challenging outlook as revenue growth has decelerated to a 10.2% year-over-year decline in 2026Q1, signaling potential market saturation for its core Lapiplasty procedure.
Despite maintaining robust gross margins near 79.3%, the company has failed to achieve operating leverage, with SG&A expenses consistently exceeding $49 million per quarter.
Investors should remain cautious as the company's cash reserves have dwindled to $9.5 million, raising significant concerns regarding the sustainability of its current business model without further capital infusion.

Verdict Logic

the company's precarious liquidity position, highlighted by a cash balance of only $9.5 million against a history of persistent net losses, suggests a high risk of future shareholder dilution.

TMCI Growth Metrics

Treace Medical Concepts, Inc. (TMCI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years29.96%

3 Years14.46%

TTM-1.66%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-15.2%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-14.39%

Return on Capital

10 Years-21.83%

5 Years-28.05%

3 Years-30.31%

Last Year-31.66%

TMCI Recent Earnings

Treace Medical Concepts, Inc. (TMCI) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)

Q2 2026Latest

May 8, 2026

Metric

Actual

Est

EPS

$0.28+9.7%

$0.31

Rev

$47M+2.7%

$46M

Q1 2026

Feb 27, 2026

Metric

Actual

Est

EPS

$0.12+21.0%

$0.15

Rev

$63M+1.1%

$62M

Q4 2025

Nov 6, 2025

Metric

Actual

Est

EPS

$0.26+7.1%

$0.28

Rev

$50M-18.7%

$62M

Q3 2025

Aug 7, 2025

Metric

Actual

Est

EPS

$0.28+3.4%

$0.29

Rev

$47M-4.9%

$50M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 8, 2026	$0.28vs $0.31+9.7%	$47Mvs $46M+2.7%
Q1 2026	Feb 27, 2026	$0.12vs $0.15+21.0%	$63Mvs $62M+1.1%
Q4 2025	Nov 6, 2025	$0.26vs $0.28+7.1%	$50Mvs $62M-18.7%
Q3 2025	Aug 7, 2025	$0.28vs $0.29+3.4%	$47Mvs $50M-4.9%

Based on last 12 quarters of dataView full earnings history →

Latest TMCI News

Recent stock market news and headlines for Treace Medical Concepts, Inc. (TMCI)

GlobeNewsWire·Jun 18, 2026

Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System

New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base

Peers Comparison

Key metrics vs top competitors for Treace Medical Concepts, Inc. (TMCI)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
TMCITreace Medical Concepts, Inc.Current	$4.56	$295.82M	-4.90	1.59%	-27.74%	-58.94%	—
ANGOAngioDynamics, Inc.	$12.98	$536.32M	-15.64	-3.76%	-10%	-17.65%	—
NVCRNovoCure Limited	$17.32	$1.97B	-14.20	8.28%	-25.66%	-50.82%	—
ATECAlphatec Holdings, Inc.	$9.33	$1.41B	-9.72	24.95%	-21.07%	-443.09%	—
OSUROraSure Technologies, Inc.	$4.37	$314.49M	-4.65	-38.1%	-61.93%	-15.09%	—
PRCTPROCEPT BioRobotics Corporation	$21.21	$1.21B	-12.33	37.22%	-31.82%	-27.7%	—

Compare TMCI vs Peers

Treace Medical Concepts, Inc. (TMCI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ANGO

Most directly comparable listed peer for TMCI.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare TMCI against a more recognizable public peer.

Peer Set

Compare Top 5

vs ANGO, NVCR, ATEC, OSUR

TMCI SEC Filings & Documents

Treace Medical Concepts, Inc. (TMCI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 8, 2026·SEC

Material company update

Apr 9, 2026·SEC

Material company update

Feb 27, 2026·SEC

10-K Annual Reports

FY 2026

Feb 27, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 27, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 8, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

Get notified when TMCI posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

TMCI Frequently Asked Questions

Treace Medical Concepts, Inc. (TMCI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Treace Medical Concepts, Inc.'s revenue?

Treace Medical Concepts, Inc. (TMCI) reported $207.3M in revenue for fiscal year 2025. This represents a 426% increase from $39.4M in 2019.

How fast is Treace Medical Concepts, Inc. growing?

Treace Medical Concepts, Inc. (TMCI) grew revenue by 1.6% over the past year. Growth has been modest.

Is TMCI profitable?

Treace Medical Concepts, Inc. (TMCI) reported a net loss of $61.0M for fiscal year 2025.

Dividend & Returns

What is TMCI's return on equity?

Treace Medical Concepts, Inc. (TMCI) has a return on equity (ROE) of -58.9%. Negative ROE indicates the company is unprofitable.

What is Treace Medical Concepts, Inc.'s free cash flow?

Treace Medical Concepts, Inc. (TMCI) had negative free cash flow of $26.0M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in TMCI back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 8, 2026

$0.28vs $0.31+9.7%

$47Mvs $46M+2.7%

Q1 2026

Feb 27, 2026

$0.12vs $0.15+21.0%

$63Mvs $62M+1.1%

Q4 2025

Nov 6, 2025

$0.26vs $0.28+7.1%

$50Mvs $62M-18.7%

Q3 2025

Aug 7, 2025

$0.28vs $0.29+3.4%

$47Mvs $50M-4.9%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

TMCITreace Medical Concepts, Inc.Current

$4.56

$295.82M

-4.90

1.59%

-27.74%

-58.94%

—

ANGOAngioDynamics, Inc.

$12.98

$536.32M

-15.64

-3.76%

-10%

-17.65%

—

NVCRNovoCure Limited

$17.32

$1.97B

-14.20

8.28%

-25.66%

-50.82%

—

ATECAlphatec Holdings, Inc.

$9.33

$1.41B

-9.72

24.95%

-21.07%

-443.09%

—

OSUROraSure Technologies, Inc.

$4.37

$314.49M

-4.65

-38.1%

-61.93%

-15.09%

—

PRCTPROCEPT BioRobotics Corporation

$21.21

$1.21B

-12.33

37.22%

-31.82%

-27.7%

—